{"id":"NCT02314637","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients","officialTitle":"Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2011-07","completion":"2011-07","firstPosted":"2014-12-11","resultsPosted":"2015-01-02","lastUpdate":"2015-08-20"},"enrollment":240,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Teneligliptin","otherNames":[]},{"type":"DRUG","name":"Teneligliptin + Sulfonylurea","otherNames":[]}],"arms":[{"label":"Teneligliptin","type":"EXPERIMENTAL"},{"label":"Teneligliptin + Sulfonylurea","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with Sulfonylurea (glimepiride) in Japanese patients with type 2 Diabetes for 52 weeks administration.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"52 weeks","effectByArm":[{"arm":"Teneligliptin","deltaMin":6,"sd":null},{"arm":"Teneligliptin + Sulfonylurea","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["25861982"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":151},"commonTop":["Nasopharyngitis","Protein urine present","Glucose urine present","Blood creatine phosphokinase increased","Upper respiratory tract inflammation"]}}